352 related articles for article (PubMed ID: 32335707)
1. Radiological findings of denosumab treatment for giant cell tumours of bone.
van Langevelde K; McCarthy CL
Skeletal Radiol; 2020 Sep; 49(9):1345-1358. PubMed ID: 32335707
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone.
Traub F; Singh J; Dickson BC; Leung S; Mohankumar R; Blackstein ME; Razak AR; Griffin AM; Ferguson PC; Wunder JS
Eur J Cancer; 2016 May; 59():1-12. PubMed ID: 26990281
[TBL] [Abstract][Full Text] [Related]
3. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study.
Chawla S; Blay JY; Rutkowski P; Le Cesne A; Reichardt P; Gelderblom H; Grimer RJ; Choy E; Skubitz K; Seeger L; Schuetze SM; Henshaw R; Dai T; Jandial D; Palmerini E
Lancet Oncol; 2019 Dec; 20(12):1719-1729. PubMed ID: 31704134
[TBL] [Abstract][Full Text] [Related]
4. [Denosumab may be a supplement to the surgical treatment of giant cell tumours of bone].
Sørensen AL; Hansen RL; Jørgensen PH
Ugeskr Laeger; 2016 Sep; 178(36):. PubMed ID: 27593237
[TBL] [Abstract][Full Text] [Related]
5. The role of Denosumab in joint preservation for patients with giant cell tumour of bone.
Perrin DL; Visgauss JD; Wilson DA; Griffin AM; Abdul Razak AR; Ferguson PC; Wunder JS
Bone Joint J; 2021 Jan; 103-B(1):184-191. PubMed ID: 33380180
[TBL] [Abstract][Full Text] [Related]
6. Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): For how long?
Palmerini E; Chawla NS; Ferrari S; Sudan M; Picci P; Marchesi E; Leopardi MP; Syed I; Sankhala KK; Parthasarathy P; Mendanha WE; Pierini M; Paioli A; Chawla SP
Eur J Cancer; 2017 May; 76():118-124. PubMed ID: 28324746
[TBL] [Abstract][Full Text] [Related]
7. Giant cell tumor of the bone: aggressive case initially treated with denosumab and intralesional surgery.
von Borstel D; A Taguibao R; A Strle N; E Burns J
Skeletal Radiol; 2017 Apr; 46(4):571-578. PubMed ID: 28188337
[TBL] [Abstract][Full Text] [Related]
8. Assessment of denosumab treatment effects and imaging response in patients with giant cell tumor of bone.
Engellau J; Seeger L; Grimer R; Henshaw R; Gelderblom H; Choy E; Chawla S; Reichardt P; O'Neal M; Feng A; Jacobs I; Roberts ZJ; Braun A; Bach BA
World J Surg Oncol; 2018 Sep; 16(1):191. PubMed ID: 30231890
[TBL] [Abstract][Full Text] [Related]
9. Clinical, radiological and pathological outcomes following treatment of primary giant cell tumour of bone with Denosumab.
Murphy B; Vodanovich D; Spelman T; Gullifer J; Slavin J; Powell G; Pang G; Choong P
ANZ J Surg; 2020 Dec; 90(12):2553-2558. PubMed ID: 32767541
[TBL] [Abstract][Full Text] [Related]
10. Giant cell tumour of bone in the denosumab era.
van der Heijden L; Dijkstra PDS; Blay JY; Gelderblom H
Eur J Cancer; 2017 May; 77():75-83. PubMed ID: 28365529
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis and monitoring denosumab therapy of giant cell tumors of bone: radiologic-pathologic correlation.
Lejoly M; Van Den Berghe T; Creytens D; Huysse W; Lapeire L; Sys G; Verstraete K
Skeletal Radiol; 2024 Feb; 53(2):353-364. PubMed ID: 37515643
[TBL] [Abstract][Full Text] [Related]
12. Utility of intraoperative magnetic resonance imaging for giant cell tumor of bone after denosumab treatment: a pilot study.
Furuta T; Kubo T; Sakuda T; Saito T; Kurisu K; Muragaki Y; Adachi N
Acta Radiol; 2022 Feb; 63(2):176-181. PubMed ID: 33517664
[TBL] [Abstract][Full Text] [Related]
13. Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab.
Palmerini E; Seeger LL; Gambarotti M; Righi A; Reichardt P; Bukata S; Blay JY; Dai T; Jandial D; Picci P
BMC Cancer; 2021 Jan; 21(1):89. PubMed ID: 33482769
[TBL] [Abstract][Full Text] [Related]
14. Radiological Assessment of Giant Cell Tumour of Bone in the Sacrum: From Diagnosis to Treatment Response Evaluation.
Langevelde KV; Vucht NV; Tsukamoto S; Mavrogenis AF; Errani C
Curr Med Imaging; 2022; 18(2):162-169. PubMed ID: 33845749
[TBL] [Abstract][Full Text] [Related]
15. Effect evaluation of denosumab combined with curettage and bone cement reconstruction in the treatment of recurrent giant cell tumor of bone around the knee joint.
Duan DK; Zhang GC; Sun BJ; Ma TX; Zhao M
Eur Rev Med Pharmacol Sci; 2023 Jun; 27(11):5039-5052. PubMed ID: 37318478
[TBL] [Abstract][Full Text] [Related]
16. Development of high-grade osteosarcoma in a patient with recurrent giant cell tumor of the ischium while receiving treatment with denosumab.
Tsukamoto S; Righi A; Vanel D; Honoki K; Donati DM; Errani C
Jpn J Clin Oncol; 2017 Nov; 47(11):1090-1096. PubMed ID: 29048579
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic and molecular features of denosumab-treated giant cell tumour of bone (GCTB): Analysis of 21 cases.
Yang L; Zhang H; Zhang X; Tang Y; Wu Z; Wang Y; Huang H; Fu X; Liu J; Hogendoorn PCW; Cheng H
Ann Diagn Pathol; 2022 Apr; 57():151882. PubMed ID: 34995868
[TBL] [Abstract][Full Text] [Related]
18. Clinical and pathological analysis of giant cell tumor of bone with denosumab treatment and local recurrence.
Hayashida K; Kawabata Y; Kato I; Kamiishi T; Matsuo K; Takeyama M; Inaba Y
J Orthop Sci; 2022 Jan; 27(1):215-221. PubMed ID: 33358447
[TBL] [Abstract][Full Text] [Related]
19. Response to Denosumab in 2 Children With Recurrent Giant Cell Tumor of the Bone With Pulmonary Metastasis.
Reddy K; Ramirez L; Kukreja K; Venkatramani R
J Pediatr Hematol Oncol; 2021 Mar; 43(2):e215-e218. PubMed ID: 31714440
[TBL] [Abstract][Full Text] [Related]
20. Preoperative denosumab treatment with curettage may be a risk factor for recurrence of giant cell tumor of bone.
Sano K; Suehara Y; Okubo T; Sasa K; Kurihara T; Akaike K; Kubota D; Torigoe T; Hasegawa N; Ishii M; Nakamura Y; Kim Y; Takagi T; Kaneko K; Hayashi T; Saito T
J Orthop Surg (Hong Kong); 2020; 28(2):2309499020929786. PubMed ID: 32539628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
